Biotech ETFs XBI and PBE diverge sharply in structure and returns, impacting investor choice.

The SPDR S&P Biotech ETF (XBI) and Invesco Biotechnology & Genome ETF (PBE) differ significantly in portfolio structure and performance. XBI uses a modified equal-weight approach across 100+ biotech stocks, favoring small- and mid-cap clinical-stage developers, resulting in a 72.6% gain over the past year. PBE focuses on about 30 large-cap, profitable biotech companies with a quality screen, returning 34.7% in the same period. XBI offers higher growth potential but more volatility, while PBE provides smoother returns and better downside protection, especially in tougher markets. Investors should choose based on risk tolerance and market outlook, with XBI favored in a rate-cutting, IPO-friendly environment and PBE preferred during credit tightening or clinical failures.